Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticles

详细信息    查看全文

• 作者：Sylvia Wagner ; Florian Rothweiler ; Marion G. Anhorn ; Daniel Sauer ; Iris Riemann ; Eike C. Weiss ; Alisa Katsen-Globa ; Martin Michaelis ; Jindrich Cinatl Jr. ; Daniel Schwartz ; Jö ; rg Kreuter ; Hagen von
• 关键词：Albumin ; Chemotherapy ; Drug delivery ; ECM (extracellular matrix) ; Integrin ; Nanoparticles
• 刊名：Biomaterials
• 出版年：2010
• 出版时间：March 2010
• 年：2010
• 卷：31
• 期：8
• 页码：2388-2398
• 全文大小：2696 K

文摘

Specific transport of anti-cancer drugs into tumor cells may result in increased therapeutic efficacy and decreased adverse events. Expression of αvβ3 integrin is enhanced in various types of cancer and monoclonal antibodies (mAbs) directed against αvβ3 integrins hold promise for anti-cancer therapy. DI17E6 is a monoclonal antibody directed against αv integrins that inhibits growth of melanomas in vitro and in vivo and inhibits angiogenesis due to interference with αvβ3 integrins. Here, DI17E6 was covalently coupled to human serum albumin nanoparticles. Resulting nanoparticles specifically targeted αvβ3 integrin positive melanoma cells. Moreover, doxorubicin loaded DI17E6 nanoparticles showed increased cytotoxic activity in αvβ3-positive melanoma cells than the free drug. Therefore, DI17E6-coupled human serum albumin nanoparticles represent a potential delivery system for targeted drug transport into αvβ3-positive cells.